SYMMETRY® − an ensemble of computational tools and methods aiming to replicate all the processes through which new drugs are discovered, developed and approved – supports several strategies to discover new drugs. Here we describe modifying the chemical structures of natural products to improve their pharmacological efficacy and ADMET profiles as well as identifying new indications....

Illustrates how new targeted therapies for type 2 diabetes can be discovered using the Prous Institute SYMMETRY® drug discovery platform. The approach has been successfully applied across other diverse therapeutic targets and disease areas, including cancer, pain and neurodegeneration. The platform aims to speed up the process of drug discovery and development, reducing time cost and attrition...

Washington D.C., USA: Prous Institute for Biomedical Research will be jointly presenting a scientific poster with the US FDA Center for Drug Evaluation and Research (CDER) at the Annual Meeting of the Society of Toxicology in Washington D.C.. The poster is titled: “Computational Modeling for QT Prolongation: A Drug Cardiovascular Safety Endpoint of Paramount Importance”. The poster wil...

Washington D.C., USA: Prous Institute’s BioEpisteme® software will be featured in a scientific poster to be presented by the US FDA Center for Drug Evaluation and Research (CDER), Office of Pharmaceutical Science (OPS), at the Annual Meeting of the Society of Toxicology in Washington D.C., March 6th-10th 2011. The poster is titled: “In silico Predictive Model for Drug-Induced Phosp...

Part C: use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities.  Describes the regulatory use of BioEpisteme and other predictive systems. Authors: Matthews EJ, Kruhlak NL, Benz RD, Aragonés Sabaté D, Marchant CA, Contrera JF. Journal: Regul Toxicol Pharmacol. 2009 Jun;54(1):43-65, PMID: 19422...